Zydus Cadila Opens New Fronts In COVID-19 Battle
US Injectables And Transdermals Business Ramp-Up Contingent on Moraiya Remediation
With seven COVID-19 treatment/prophylactic candidates lined up, India's Zydus Cadila is unleashing all it can to combat the disease. Meanwhile, the firm has also offered an update on the state of its injectables and transdermals business in the US, which is contingent on resolving deficiencies at its Moraiya plant.
You may also be interested in...
Join the Asia content team for a wide-ranging overview and analysis of developments and trends in the region, including coronavirus vaccines in China, Korean developments in NASH, digital health shifts, Indian corporate performance and Japanese deal trends.
India has rolled out draft guidelines for development of vaccines with special focus on COVID-19 vaccines, drawing from those of other regulatory bodies and the WHO. Experts suggest the primary efficacy endpoint of minimum 50% is acceptable given that vaccines against respiratory diseases are difficult to develop though not necessarily enough to snuff out a pandemic.
The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate